SCHEMBL14711368

SCHEMBL14711368

COC(=O)[C@@H]1CCN(c2ccc(N)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.56
NOTUM Q6P988 5/20 0.49
LMNA P02545 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CASP6 P55212 1/20 0.45
GFER P55789 1/20 0.45
KDM4E B2RXH2 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA13 Q8N1Q1 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14712096 1.00 MAPT (0.56) MAPTNOTUMLMNAMEN1KMT2A
SCHEMBL14711365 0.92 MAPT (0.47) MAPTNOTUMMEN1KMT2ACASP6
SCHEMBL14712094 0.92 MAPT (0.47) MAPTNOTUMMEN1KMT2ACASP6
SCHEMBL16611364 0.91 MAPT (0.66) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3713571 0.88 NAMPT (0.48) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL20887605 0.87 MAPT (0.57) MAPTNOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL20887690 0.87 MAPT (0.57) MAPTNOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL22434593 0.87 MAPT (0.57) MAPTNOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL19904630 0.87 MAPT (0.57) MAPTNOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL20840870 0.85 NOTUM (0.68) MAPTNOTUMLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 MAPT 4564/4885NOTUM 1014/4885LMNA 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.